IDT partners with SOPHiA GENETICS to increase access to clinical-grade technologies

Leading genomics solutions, combined with advanced analytics, provide benefits to hospitals and patients

CORALVILLE, IA (January 15, 2020)Integrated DNA Technologies (IDT), a leading comprehensive genomics solutions provider, announced an expanded global partnership with SOPHiA GENETICS, a leader in Data-Driven Medicine. Together, the superior enrichment products of IDT combined with SOPHiA GENETICS’s universal analytics platform and advanced multimodal solutions, provide powerful solutions for clinical researchers.

When bundling IDT’s reagents with the SOPHiA Platform, researchers will benefit from sophisticated analysis technology and the collective intelligence of the SOPHiA community. It will help accurately detect and characterize genomic variants and share insights in the healthcare ecosystem. In addition, users can also take advantage of the SOPHiA Set-Up Program which is designed to support the implementation of Next-Generation Sequencing (NGS)-based testing for genetic diseases. The Set-Up Program is an efficient and reliable process that establishes and demonstrates the analytical performance of a test prior to adoption. The inclusion of superior enrichment products from IDT’s NGS portfolio, which meet the highest standards of quality and performance, plays an essential role in bringing accurate and precise solutions to hospitals globally.

 

Trey Martin, President of IDT commented, “IDT recognizes that analysis and interpretation of NGS data presents challenges to researchers and clinicians, so we are excited to offer the combination of the sophisticated SOPHiA Platform with our Exome v1 and the soon to be released xGen Exome Research Panel v2. This will give labs a complete solution to get the very best exome data available on the market.”

 

Mirna Jarosz, General Manager of NGS at IDT noted, “We are excited to expand our working relationship with SOPHiA GENETICS to further impact clinical genomics research. We share a common goal of providing best-in-class solutions that ultimately help improve people’s lives. By providing a foundation of the most consistent and highest quality reagents, IDT is supporting SOPHiA in the all-important steps of translating data into actionable treatments for patients. Following our recent launch of NGS Discovery Pools for early stage discovery, our partnership with SOPHiA GENETICS further expands our ability to offer solutions for the entire precision medicine journey, from discovery to diagnostics.”

 

IDT and SOPHiA GENETICS have teamed up for a number of years, including the development of a first of its kind In Vitro Diagnostics (IVD) marked SOPHiA Hereditary Cancer Solution in 2016. SOPHiA GENETICS has launched several additional IVD solutions since then, providing simple and fast procedures for healthcare professionals committed to serving patients by bringing clinical diagnostics in-house.

 

Jurgi Camblong, CEO and co-founder of SOPHiA GENETICS, commented, “Our strong relationship with IDT has enabled us to further accelerate the democratization in clinical genomics and better serve patients around the world. The universal SOPHiA Platform and genomic solutions make us the partner of choice for best-in-class reagent providers to bring end-to-end, highly-accurate and reliable outcomes to their clients. With the combined powers of SOPHiA’s high performance analytical capabilities and the world-class products that IDT has pioneered, many diseases the world currently faces may soon become more manageable and far easier to detect. The future of precision medicine is made brighter with this collaboration.”

 

For more information, please visit www.idtdna.com and www.SOPHIAGENETICS.com.     

 

Follow IDT (@idtdna) and SOPHiA GENETICS (@SOPHiAGENETICS) on twitter for real-time updates and insights.

The SOPHiA Platform is for Research Use Only in the USA.

Subscribe to our mailing list

* required
Which information would you like to receive ?

SOPHiA GENETICS will use your email address to send you SOPHiA GENETICS newsletters and all relevant information about us.
You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at info@sophiagenetics.com.
By subscribing, you agree that we may process your data in accordance with our privacy policy.

Latest news

SOPHiA GENETICS taps ex-Foundation Medicine CEO as chairman
Read more

L’ADN de SOPHiA GENETICS s’américanise
Read more